The Goldman Sachs Group Issues Pessimistic Forecast for Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price

Olema Pharmaceuticals (NASDAQ:OLMA) had its price target decreased by The Goldman Sachs Group from $38.00 to $27.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. The Goldman Sachs Group’s price target would suggest a potential upside of 79.28% from the stock’s current price.

OLMA has been the subject of a number of other research reports. JPMorgan Chase & Co. increased their target price on shares of Olema Pharmaceuticals from $29.00 to $32.00 and gave the company an “overweight” rating in a research report on Tuesday, November 18th. Guggenheim dropped their price target on shares of Olema Pharmaceuticals from $40.00 to $38.00 and set a “buy” rating on the stock in a research report on Tuesday. TD Cowen reiterated a “buy” rating on shares of Olema Pharmaceuticals in a report on Monday, March 9th. Citigroup raised their price objective on shares of Olema Pharmaceuticals from $60.00 to $62.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, Stifel Nicolaus started coverage on Olema Pharmaceuticals in a report on Wednesday, February 11th. They set a “buy” rating and a $48.00 target price on the stock. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $42.00.

Olema Pharmaceuticals Trading Down 9.3%

Shares of OLMA stock opened at $15.06 on Wednesday. Olema Pharmaceuticals has a 1 year low of $2.86 and a 1 year high of $36.26. The firm has a market capitalization of $1.03 billion, a PE ratio of -8.10 and a beta of 1.92. The stock has a fifty day moving average of $23.81 and a two-hundred day moving average of $18.73. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.03 and a current ratio of 8.03.

Olema Pharmaceuticals (NASDAQ:OLMA) last issued its quarterly earnings results on Monday, March 16th. The company reported ($0.50) EPS for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.01. As a group, research analysts expect that Olema Pharmaceuticals will post -2.33 EPS for the current year.

Insider Transactions at Olema Pharmaceuticals

In other Olema Pharmaceuticals news, insider Shawnte Mitchell sold 25,000 shares of the company’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $24.25, for a total value of $606,250.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Shane William Charles Kovacs sold 100,000 shares of the stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $28.73, for a total value of $2,873,000.00. Following the sale, the insider owned 139,727 shares of the company’s stock, valued at $4,014,356.71. This trade represents a 41.71% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 805,501 shares of company stock valued at $23,003,832 in the last 90 days. 16.36% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Olema Pharmaceuticals

Several hedge funds have recently modified their holdings of the stock. Ameritas Investment Partners Inc. increased its stake in Olema Pharmaceuticals by 55.4% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,080 shares of the company’s stock worth $26,000 after purchasing an additional 2,168 shares in the last quarter. EverSource Wealth Advisors LLC lifted its stake in Olema Pharmaceuticals by 9,476.9% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,245 shares of the company’s stock valued at $31,000 after buying an additional 1,232 shares in the last quarter. Torren Management LLC acquired a new position in shares of Olema Pharmaceuticals in the fourth quarter worth about $44,000. Russell Investments Group Ltd. acquired a new position in shares of Olema Pharmaceuticals in the third quarter worth about $53,000. Finally, American Century Companies Inc. purchased a new position in shares of Olema Pharmaceuticals in the second quarter worth approximately $54,000. 91.78% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Olema Pharmaceuticals

Here are the key news stories impacting Olema Pharmaceuticals this week:

• Positive Sentiment: Q4 earnings surprised slightly to the upside — Olema reported ($0.50) EPS vs. consensus ($0.51), which triggered positive investor reaction and immediate share strength. Press Release OLMA Stock Jumps After Q4
• Positive Sentiment: HC Wainwright raised near‑term and multi‑year EPS forecasts across 2026–2030 (slightly less negative EPS), reiterated a “Buy” rating and kept a $38 price target — signaling improving economics expectations for the company. This analyst lift supports further upside sentiment. Analyst Note
• Positive Sentiment: Citigroup raised its price target sharply (from $60 to $62) and maintains a buy view — a material, bullish institutional price-target move that can draw attention from momentum and institutional buyers. Benzinga: Citigroup
• Positive Sentiment: Large external interest tied to Olema’s breast‑cancer drug: reports note a ~$68.7M wager related to the program targeting a 2027 launch, which underscores investor confidence and potential financing/support for commercial plans. Globe and Mail: $68.7M Bet
• Positive Sentiment: Clinical visibility: Olema (via Olema Oncology) will present preclinical data for palazestrant and OP‑3136 at AACR 2026 — continued scientific disclosure can reduce clinical uncertainty and support longer‑term valuation. Business Insider: AACR Presentation
• Negative Sentiment: Guggenheim trimmed its price target (from $40 to $38) though it kept a “Buy” rating — a slight headwind as some investors may see this as less bullish relative to higher targets. Benzinga: Guggenheim

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.